StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

5H-Dibenz(b,f)azepin-5-propanamin, 10,11-dihydro-N,N-dimethyl-monohydrochlorid

Imipramine Hydrochloride

HCID 8228
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
113-52-0
Standard-SMILES
CN(C)CCCN1c2ccccc2CCc2ccccc21.Cl
InChIKey
XZZXIYZZBJDEEP-UHFFFAOYSA-N
Summenformel
C19H25ClN2
Durchschnittliche Molmasse
316,9 g/mol
Monoisotopische Masse
316,1706265

Überblick

Imipramine Hydrochloride is the hydrochloride salt form of imipramine, a synthetic tricyclic derivative, antidepressant Imipramine enhances monoamine neurotransmission in certain areas of the brain. It also induces sedation through histamine 1 receptor blockage; hypotension through beta-adrenergic blockage; and diverse parasympatholytic effects. Imipramine has less sedative effect than other members of its therapeutic family. It is used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. (NCI04)

Namen und Bezeichner

Bevorzugter Name
Imipramine Hydrochloride
IUPAC
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine;hydrochloride
Lokaler Name
5H-Dibenz(b,f)azepin-5-propanamin, 10,11-dihydro-N,N-dimethyl-monohydrochlorid
Englischer Name
Imipramine hydrochloride
Summenformel
C19H25ClN2
Molmasse
316.87

Namen und Synonyme

Imipramine hydrochloride113-52-0Imipramine HclTofranilPresaminePryleuganPramineAntideprin hydrochlorideImipramini hydrochloridumPraminilSarimpDTXSID7040738
Weitere Namen anzeigen
g22355imidolia-pramimavateiprogendeprinoldynazinaefuranol
BKE5Q1J60UNSC-114900G-223555H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, monohydrochlorideCHEBI:5882DTXCID5020738NSC1149005H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, monohydrochloride

Datenbank-Bezeichner

CAS
113-52-0
PubChem CID
8228
DTXSID
DTXSID7040738
ChEMBL
CHEMBL1692
UNII
BKE5Q1J60U
EC Number
204-030-7

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

Polarare Oberfläche (TPSA)
6,5 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
2
Frei drehbare Bindungen
4
Schwere Atome
22
Formalladung
0
Komplexität
291

Experimentelle und physikochemische Eigenschaften

Solubility>47.5 [ug/mL] (The mean of the results at pH 7.4)
Human Drugs · 3 Einträge

Breast Feeding; Lactation; Milk, Human; Antidepressive Agents; Antidepressive Agents, Tricyclic

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Collision Cross Section165.1 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
168 · 168-1700C
Flammpunkt
9 ℃ · 9℃
storage temp.
2 · 2-8°C
Löslichkeit
2 O: · H2O: 50 mg/mL
Aggregatzustand
crystalline
Farbe
white
PH
4.2 · 4.2~5.2(100g/l,25℃)
Wasserlöslichkeit
Soluble in water
Merck
14 · 14,4920
InChI
1S/C19H24N2.ClH/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21;/h3-6,8-11H,7,12-15H2,1-2H3;1H
InChIKey
XZZXIYZZBJDEEP-UHFFFAOYSA-N
SMILES
Cl[H].CN(C)CCCN1c2ccccc2CCc3ccccc13
CAS Datenbank
113 · 113-52-0(CAS DataBase Reference)
EPA chemische Informationen
5 H-Dibenz[b,f]azepine-5-propanamine, · 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, monohydrochloride (113-52-0)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 92 reports by companies from 4 notifications to the ECHA C&L Inventory.

Gefahrenhinweise

Regulatory InformationImipramine hydrochloride: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, monohydrochloride: Human health tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxikologische Informationen

Treatment · 1 Eintrag

Obtain an ECG and immediately initiate cardiac monitoring. Protect the patient's airway, establish an intravenous line and initiate gastric decontamination. A minimum of 6 hours of observation with cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias and/or conduction blocks, and seizures is necessary. If signs of toxicity occur at anytime during this period, extended monitoring is required. (L1712)

Exposure RoutesRapidly and well absorbed after oral administration. Bioavailability is approximately 43%. Peak plasma concentrations usually attained 1 - 2 hours following oral administration. Absorption is unaffected by food.
Toxicity Summary · 1 Eintrag

Imipramine works by inhibiting the neuronal reuptake of the neurotransmitters norepinephrine and serotonin. It binds the sodium-dependent serotonin transporter and sodium-dependent norepinephrine transporter preventing or reducing the reuptake of norepinephrine and serotonin by nerve cells. Depression has been linked to a lack of stimulation of the post-synaptic neuron by norepinephrine and serotonin. Slowing the reuptake of these neurotransmitters increases their concentration in the synaptic cleft, which is thought to contribute to relieving symptoms of depression. In addition to acutely inhibiting neurotransmitter re-uptake, imipramine causes down-regulation of cerebral cortical beta-adrenergic receptors and sensitization of post-synaptic serotonergic receptors with chronic use. This leads to enhanced serotonergic transmission.

Signs and Symptoms · 1 Eintrag

Antagonism of the histamine H<sub>1</sub> and &alpha;<sub>1</sub> receptors can lead to sedation and hypotension. Antimuscarinic and anticholinergic side effects such as blurred vision, dry mouth, constipation and urine retention may occur. Cardiotoxicity may occur with high doses of imipramine. Cardiovascular side effects in postural hypotension, tachycardia, hypertension, ECG changes and congestive heart failure. Psychotoxic effects include impaired memory and delirium. Induction of hypomanic or manic episodes may occur in patients with a history of bipolar disorder. Withdrawal symptoms include GI disturbances (e.g. nausea, vomiting, abdominal pain, diarrhea), anxiety, insomnia, nervousness, headache and malaise.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Imipramine hydrochloride

vLess-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD50: 355 to 682 mg/kg (oral, rat).

Sicherheitsdaten

wgk
3
tsca
TSCA listed
ridadr
UN 1230 3/PG 2
hs_code
2933995800
RTECS-Nr.
HO1925000
risk_code
23/25-36/38-36/37/38-22-39/23/24/25-23/24/25-11
Toxizität
LD50 in mice, rats (mg/kg): 400, 490 orally; 110, 90 i.p. (Tobe)
hazard_code
Xn,T,F
safety_code
7-16-24-33-45-36-26-36/37
Speicherklasse
6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials
Hazard Classifications
Acute Tox. 2 Oral

Chemie und Industrie

Pharmakologische Informationen

Metabolism/Metabolites · 1 Eintrag

Exclusively metabolized by the liver. Imipramine is converted in the liver by various CYP isoenzymes (e.g. CYP1A2, CYP2D6, CYP3A4, CYP2C9) to active metabolites desipramine and 2-hydroxydesipramine. Route of Elimination: Approximately 40% of an orally administered dose is eliminated in urine within 24 hours, 70% in 72 hours. Small amounts are eliminated in feces via the biliary elimination. Half Life: Imipramine - 8-20 hours; Desipramine (active metabolite) - up to 125 hours

FDA Pharmacological Classification · 2 Einträge

IMIPRAMINE HYDROCHLORIDE

Tricyclic Antidepressant [EPC]

MeSH Pharmacological Classification · 2 Einträge

Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system.

Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.

Verwendung und Herstellung

Uses · 1 Eintrag

For the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older. May also be used to manage panic disorders, with or without agoraphobia, as a second line agent in ADHD, management of eating disorders, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, and for symptomatic treatment of postherpetic neuralgia.

General Manufacturing Information5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, hydrochloride (1:1): ACTIVE

Anwendungen

VerwendenImipramine hydrochloride is used as a serotonin uptake inhibitor. It mainly used in the treatment of major depression and enuresis (inability to control urination). It has also been evaluated for use in panic disorder.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Diphenyl10,11-Dihydro-N,N-dimethyl-5H-dibenz(b,f)azepin-5-propanaminPerhydroazepinNatriumamidHydrogenchlorid10,11-Dihydro-5H-dibenz[b,f]azepin

Zugehörige Reaktionen

11
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 335046
HRID 335046als Edukt
Reaktionsgleichung von HRID 536784
HRID 536784als Edukt
Reaktionsgleichung von HRID 536785
HRID 536785als Edukt
Reaktionsgleichung von HRID 1484197
HRID 1484197als Edukt
Reaktionsgleichung von HRID 1484198
HRID 1484198als Edukt
Reaktionsgleichung von HRID 1664118
HRID 1664118als Produktals Edukt
Reaktionsgleichung von HRID 2035404
HRID 2035404als Edukt
Reaktionsgleichung von HRID 2035405
HRID 2035405als Edukt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung